iPSC-Derived Immunotherapies Congress

iPSCs show great promise in addressing the current challenges surrounding cost and demand associated with current cell therapies on the market, but with genomic stability concerns and manufacturing complexities, these therapies are still at early stages of clinical progression. This event will highlight techniques used to develop safe, differentiated and efficacious therapies to pass through regulatory hurdles. Explore key techniques focused on addressing issues in teratoma formation, genomic instability, off-target modifications, ex vivo gene editing to target immunogenicity, and feeder system complexity.

This event is your opportunity to analyze developments in bringing iPSC-derived immunotherapies from bench to bedside to deliver long-lasting, safe, effective therapeutics.